Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JW (Cayman) Therapeutics CoJWCTF -4.38%26 3-Year EBITDA Growth Rate is 15.90% as of Dec. 2025, which is 12% above its 10-year median of 14.20. GuruFocus rates JWCTF with a GF Score™ of 26/100 and a GF Value™ of $0.59 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,129 Biotechnology companies, JW (Cayman) Therapeutics Co ranks better than 51.2% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of JW (Cayman) Therapeutics Co was 50.90% per year. The lowest was -35.70% per year. And the median was 14.20% per year.
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
JW (Cayman) Therapeutics Co 3-Year EBITDA Growth Rate Related Terms
JWCTF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate falls into.
JW (Cayman) Therapeutics Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.90% mean?
JW (Cayman) Therapeutics Co (JWCTF) has a 3-Year EBITDA Growth Rate of 15.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for JW (Cayman) Therapeutics Co and its competitors. This is 12% above median its historical median of 14.20. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #551 out of 1129 companies in the Biotechnology industry, placing it in the top 48.8%.
Is JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate too high?
JW (Cayman) Therapeutics Co's current 3-Year EBITDA Growth Rate of 15.90% is 12% above median its 10-year median of 14.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. JW (Cayman) Therapeutics Co's value of 15.90% is 6.7% above this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #551 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #551 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts JW (Cayman) Therapeutics Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. JW (Cayman) Therapeutics Co's value of 15.90% is 6.7% above this benchmark. While the company's 10-year median is 14.20 vs. the industry median of 14.90, JW (Cayman) Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current 3-Year EBITDA Growth Rate of 15.90% is 6.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current 3-Year EBITDA Growth Rate is 15.90%, which is 12% above median its own 10-year median of 14.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.59, compared to a current price of $0.20 — trading 65.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 15.90%, which is 12% above median its 10-year median of 14.20 and 6.7% above the Biotechnology industry median of 14.90. JW (Cayman) Therapeutics Co's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current 3-Year EBITDA Growth Rate is 15.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.20 is trading 65.7% below its estimated GF Value™ of $0.59.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
3-Year EBITDA Growth Rate: 15.90% (12% above median its 10-year median of 14.20)
GF Value™: $0.59 vs. price of $0.20 (65.7% below fair value)
Industry Position: 6.7% above the Biotechnology median (#551 of 1129)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
26GF Score
Get the complete analysis for JWCTF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
